• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

HERCEPTIN Drug Record

  • Summary
  • Interactions
  • Claims
  • HERCEPTIN wikidata:Q29005931

    Alternate Names:

    rxcui:101306

    Drug Info:

    (0 More Sources)

    Publications:

    Yakes et al., 2002, Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action., Cancer Res.
    Láng et al., 2006, [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer]., Magy Onkol
    Safran et al., 2004, Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu., Cancer Invest.
    Zhang et al., 2005, Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer., Mol. Cell Proteomics
  • HERCEPTIN   HSPB2

    Interaction Score: 4.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16048908


    Sources:
    NCI

  • HERCEPTIN   PIK3CG

    Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12124352


    Sources:
    NCI

  • HERCEPTIN   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17216002 15581051


    Sources:
    NCI

  • NCI: HERCEPTIN

    • Version: 14-September-2017

    Alternate Names:
    C1647 NCI drug code

    Drug Info:

    Publications:
    Yakes et al., 2002, Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action., Cancer Res.
    Láng et al., 2006, [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer]., Magy Onkol
    Safran et al., 2004, Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu., Cancer Invest.

  • Wikidata: wikidata:Q29005931

    • Version: 12-August-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21